Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Kalaris Therapeutics Q1 EPS $(2.52) Misses $(1.17) Estimate

Author: Benzinga Newsdesk | May 14, 2025 08:13am
Kalaris Therapeutics (NASDAQ:KLRS) reported quarterly losses of $(2.52) per share which missed the analyst consensus estimate of $(1.17) by 115.38 percent. This is a 3.08 percent increase over losses of $(2.60) per share from the same period last year.

Posted In: KLRS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist